New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 10, 2021 - The FDA approved Merck’s Keytruda (pembrolizumab), in combination with Eisai’s Lenvima (lenvatinib), for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
Download PDF
Return to publications
